DRD2 and schizophrenia: Furthermore, because D2 dopamine receptors are the primary target of mainstay antipsychotic treatments and because schizophrenia has been associated with both diminished thalamic [15] and elevated striatal [3] D2/3 receptor availability in meta-analytic studies, we secondarily tested the hypothesis that TRS polygenic risk burden might also be associated with differences in D2/3 dopamine receptor availability.